Pricing Log in Create free account

Aytu BioPharma, Inc. (AYTU) vs SCYNEXIS, Inc. (SCYX)

Aytu BioPharma, Inc. and SCYNEXIS, Inc. are both Drug Manufacturers Specialty & Generic companies. SCYNEXIS, Inc. is the larger, with a market value of $34.8M against $19.9M — 1.8× the size. SCYNEXIS, Inc. grew revenue faster over the last twelve months: 682.5% against −13.3%. Aytu BioPharma, Inc. has the higher net margin (−24.8% vs −49.7%) and the higher return on invested capital (−20.0% vs −110.7%). Across the 18 metrics below, Aytu BioPharma, Inc. leads on 9 and SCYNEXIS, Inc. on 9.

Valuation

Metric AYTU SCYX Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.45
P/S 0.39 2.01 2.11
P/B 0.64 0.62 1.69
Price to free cash flow 6.97 n/m 15.98
EV/EBITDA n/m n/m 12.21
EV/Sales 0.23 0.64 2.79
Earnings yield (74.86%) (59.71%) (15.61%)
Free cash flow yield 14.35% (32.20%) 0.00%

Profitability

Metric AYTU SCYX Drug Manufacturers Specialty & Generic median
Gross margin 63.95% 100.00% 53.51%
Operating margin (14.44%) (109.90%) 0.00%
Net margin (24.76%) (49.74%) (2.31%)
Free cash flow margin 5.62% (64.67%) 0.00%
Return on equity (52.55%) (18.38%) (0.80%)
Return on assets (12.44%) (15.09%) (1.67%)
Return on invested capital (19.99%) (110.72%) 0.00%

Growth

Metric AYTU SCYX Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (13.27%) 682.47% 5.22%
EPS growth (last fiscal year) 46.30% 61.36% 42.91%
Revenue growth, 5-year CAGR (2.59%) 179.40% 7.24%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AYTU SCYX Drug Manufacturers Specialty & Generic median
Debt to equity 0.48 0.00 0.04
Current ratio 1.13 9.65 2.46
Net debt to EBITDA 2.17 2.54 1.01

Dividend

Metric AYTU SCYX Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.47%
Payout ratio — — 0.28

Size

Metric AYTU SCYX Drug Manufacturers Specialty & Generic median
Market cap 19.89m 34.84m 300.78m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack